down arrow

Sagimet Biosciences, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US7867001049
USD
6.35
0.26 (4.35%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

6.196.55

52 Week

1.7311.41
Valuation
Technical
Day's Volume

CASH

809.71 k

Shareholding (Mar 2025)

FII

7.58%

Held by 33 FIIs

DII

55.86%

Held by 22 DIIs

Promoter

17.53%

How big is Sagimet Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Sagimet Biosciences, Inc. has a market capitalization of 211.04 million and reported net sales of 0.00 million with a net profit of -57.12 million over the last four quarters. The company's balance sheet shows shareholder's funds of 155.81 million and total assets of 160.26 million.

As of Jun 18, Sagimet Biosciences, Inc. has a market capitalization of 211.04 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -57.12 million during the same period.<BR><BR>As of Dec 24, the company's balance sheet shows shareholder's funds of 155.81 million and total assets amounting to 160.26 million.

Read More

What does Sagimet Biosciences, Inc. do?

22-Jun-2025

Sagimet Biosciences, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $18 million and a market cap of $211.04 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -41.09%.

Overview: <BR>Sagimet Biosciences, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Profit: -18 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 211.04 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -41.09% <BR>Price to Book: 1.52<BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Read More

Is Sagimet Biosciences, Inc. overvalued or undervalued?

25-Jun-2025

As of November 14, 2024, Sagimet Biosciences, Inc. is considered overvalued and has moved from a risky to a "does not qualify" valuation grade due to negative financial metrics, including a price-to-book ratio of 1.23, an ROE of -41.09%, and unfavorable comparisons to peers, despite a recent stock return of 142.32%.

As of 14 November 2024, the valuation grade for Sagimet Biosciences, Inc. has moved from risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued given its negative performance metrics, including a price-to-book ratio of 1.23 and a return on equity (ROE) of -41.09%. Additionally, the EV to EBITDA and EV to EBIT ratios are both at -0.40, reflecting a troubling financial situation.<BR><BR>In comparison to its peers, Sagimet's performance is starkly unfavorable. For instance, Fusion Pharmaceuticals, Inc. has a P/E ratio of -17.58, while Rigel Pharmaceuticals, Inc. stands out as very attractive with a P/E of 9.21. The recent stock performance of Sagimet, which has returned 142.32% over the past month, contrasts sharply with its valuation metrics, reinforcing the notion that it may be overvalued in the current market context.

Read More

Is Sagimet Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Sagimet Biosciences, Inc. has a mildly bullish trend, supported by daily moving averages, but tempered by mildly bearish weekly indicators and a strong year-to-date return of 50.0%, significantly outperforming the S&P 500.

As of 1 August 2025, the technical trend for Sagimet Biosciences, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating mild bullishness. However, the weekly MACD and KST are mildly bearish, and the Bollinger Bands show a bearish signal on the weekly timeframe, which tempers the overall bullish outlook. The Dow Theory also reflects a mildly bearish stance on both weekly and monthly timeframes. <BR><BR>In terms of performance, the stock has returned 50.0% year-to-date and 99.7% over the past year, significantly outperforming the S&P 500, which has returned 12.22% and 17.14% in the same periods, respectively.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 218 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.96

stock-summary
Return on Equity

-45.62%

stock-summary
Price to Book

1.67

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-13.49%
0%
-13.49%
6 Months
74.93%
0%
74.93%
1 Year
19.59%
0%
19.59%
2 Years
67.55%
0%
67.55%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Sagimet Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Sagimet Biosciences, Inc. technically bullish or bearish?

As of 1 August 2025, the technical trend for Sagimet Biosciences, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven primarily by the daily moving averages indicating mild bullishness. However, the weekly MACD and KST are mildly bearish, and the Bollinger Bands show a bearish signal on the weekly timeframe, which tempers the overall bullish outlook. The Dow Theory also reflects a mildly bearish stance on both weekly and monthly timeframes. In terms of performance, the stock has returned 50.0% year-to-date and 99.7% over the past year, significantly outperforming the S&P 500, which has returned 12.22% and 17.14% in the same periods, respectively....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
31.60%
EBIT Growth (5y)
-213.04%
EBIT to Interest (avg)
-40.87
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0.01
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.21%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.23
EV to EBIT
-0.40
EV to EBITDA
-0.40
EV to Capital Employed
-4.70
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-41.09%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 23 Schemes (18.96%)

Foreign Institutions

Held by 33 Foreign Institutions (7.58%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -28.40% vs -19.12% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.90",
          "val2": "-10.60",
          "chgp": "-12.26%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.40",
          "val2": "-8.10",
          "chgp": "-28.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -63.44% vs 8.52% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "2.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-54.50",
          "val2": "-30.70",
          "chgp": "-77.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-45.60",
          "val2": "-27.90",
          "chgp": "-63.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-15,370.00%",
          "chgp": "1,537.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-11.90
-10.60
-12.26%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-10.40
-8.10
-28.40%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -28.40% vs -19.12% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
2.00
-100.00%
Operating Profit (PBDIT) excl Other Income
-54.50
-30.70
-77.52%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-45.60
-27.90
-63.44%
Operating Profit Margin (Excl OI)
0.00%
-15,370.00%
1,537.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -63.44% vs 8.52% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Sagimet Biosciences, Inc. stock-summary
stock-summary
Sagimet Biosciences, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."